Spinal Muscular Atrophy Type 3
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Spinal Muscular Atrophy Type 3

What is the definition of Spinal Muscular Atrophy Type 3?
Spinal muscular atrophy type 3 (SMA3) is a mild form of an inherited (genetic) neuromuscular disease characterized by decreased muscle tone and weakness (atrophy). Spinal muscular atrophy type 3 is caused by a degeneration of the lower motor neurons in the brain stem and spinal cord that control muscle movement. Spinal muscular atrophy type 3 mainly affects infants and children.
What are the symptoms of Spinal Muscular Atrophy Type 3?
Symptoms of spinal muscular atrophy type 3 usually appear after the first 18 months of life but can also have a later onset in early adulthood. Symptoms of spinal muscular atrophy include mild muscle weakness, difficulty walking, running, and climbing up and down stairs, and frequent respiratory infections.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Spinal Muscular Atrophy Type 3?
There is currently no cure for spinal muscular atrophy type 3. Promising new treatments include disease-modifying therapies that stimulate the production of the spinal motor neuron protein (SMP), such as intrathecal (injected into spinal canal) Nusinersin (Spinraza) and oral risdaplam (Evrysdi). Other treatments for spinal muscular atrophy type 3 are mainly focused on alleviating symptoms and improving quality of life and may include physical therapy; occupational therapy; and the use of assistive devices, such as braces crutches, walkers and wheelchairs.
Who are the top Spinal Muscular Atrophy Type 3 Local Doctors?
Distinguished in Spinal Muscular Atrophy Type 3
Distinguished in Spinal Muscular Atrophy Type 3

Vanderbilt Medical Group- Teleneurology

1161 21st Ave South, A-0118 Medical Center North, 
Nashville, TN 
Languages Spoken:
English
Offers Telehealth

. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy (SMA), Guillain-Barre Syndrome, and Gamma Knife Radiosurgery.

Mohammad A. Khoshnoodi
Advanced in Spinal Muscular Atrophy Type 3
Advanced in Spinal Muscular Atrophy Type 3

Reading Hospital

420 South 5th Avenue, 
West Reading, PA 
Languages Spoken:
English

. Dr. Khoshnoodi is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Peripheral Neuropathy, Guillain-Barre Syndrome, Chronic Polyradiculoneuritis, and Miller-Fisher Syndrome.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Spinal Muscular Atrophy Type 3
Elite in Spinal Muscular Atrophy Type 3

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
Languages Spoken:
English
Offers Telehealth

Richard Finkel is a Pediatrics provider in Memphis, Tennessee. Dr. Finkel is rated as an Elite provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. His top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 3, and Spinal Muscular Atrophy Type 2.

What are the latest Spinal Muscular Atrophy Type 3 Clinical Trials?
Identification of Gait-related Digital Biomarkers of Bone Health in Spinal Muscular Atrophy

Summary: The objective of this study is to understand how spatiotemporal and kinetic gait parameters are associated with bone health in pwSMA who are receiving DMT. We hypothesize that gait parameters are associated with BMD and can determine fracture risk in pwSMA. This is an observational study that involves one in-clinic visit (approximately 3 hours) with remote follow-up visits (approximately 15 minute...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA)

Summary: This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects \<2 years old with 5q autosomal recessive SMA who have delayed motor milestones for their age attributed to SMA at the discretion of the Investigator or a Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score...